Pharmacogenetics Approach for the Improvement of COVID-19 Treatment
The treatment of coronavirus disease 2019 (COVID-19) has been a challenge. The efficacy of several drugs has been evaluated and variability in drug response has been observed. Pharmacogenetics could explain this variation and improve patients’ outcomes with this complex disease; nevertheless, severa...
Main Authors: | Ingrid Fricke-Galindo, Ramcés Falfán-Valencia |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/13/3/413 |
Similar Items
-
CLOPIDOGREL PHARMACOGENETICS
by: A. N. Meshkov
Published: (2016-01-01) -
Use of Pharmacogenetic Drugs by the Dutch Population
by: Mohammad A. Alshabeeb, et al.
Published: (2019-07-01) -
Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case
by: M. A. Andreyanova, et al.
Published: (2018-11-01) -
Pharmacogenetic Tests in the Nephrological Clinic
by: D.D. Ivanov, et al.
Published: (2016-10-01) -
Pharmacokinetics and Pharmacogenetics of Apixaban
by: A. V. Savinova, et al.
Published: (2020-11-01)